<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03187314</url>
  </required_header>
  <id_info>
    <org_study_id>HangzhouCH08</org_study_id>
    <nct_id>NCT03187314</nct_id>
  </id_info>
  <brief_title>Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer</brief_title>
  <official_title>Phase II Study of Radiation Therapy With Anti-PD-1 Antibody SHR-1210 in Treating Patients With Unresectable Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangzhou Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hangzhou Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of radiation therapy&#xD;
      combined with anti-PD-1 antibody SHR-1210 in patients with esophageal cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>4-8 weeks</time_frame>
    <description>ORR was evaluated 4-8 weeks after completion of RT and was recorded according to RECIST, version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>year 0 - year 1</time_frame>
    <description>Incidence of treatment-emergent adverse events would be assessed based on the common toxicity criteria for adverse events version 4.0 (CTCAE v4.0) and EORTC criterion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local-regional free survival (LRFS)</measure>
    <time_frame>year 0 - year 3</time_frame>
    <description>LRFS was calculated from the date of treatment initiation to the date of documented failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>year 0 - year 3</time_frame>
    <description>OS was determined as the time (in months) between the first day of therapy and the last follow-up or the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQoL)</measure>
    <time_frame>From baseline to one year after RT.</time_frame>
    <description>HRQoL measured by standardized EORTC questionaires (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQoL)</measure>
    <time_frame>From baseline to one year after RT.</time_frame>
    <description>HRQoL measured by standardized EORTC questionaires (EORTC QLQ-OES18)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Esophageal Diseases</condition>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation to 60 Gy, 5 x per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210</intervention_name>
    <description>SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age:18-75 years, male or femal.&#xD;
&#xD;
          2. Histologically or cytologically confirmed Squamous Cell Carcinoma of the Esophagus,&#xD;
             locally advanced, unresectable disease.&#xD;
&#xD;
          3. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.&#xD;
&#xD;
          4. Can provide either a newly obtained or archival tumor tissue sample.&#xD;
&#xD;
          5. ECOG 0-1.&#xD;
&#xD;
          6. Life expectancy of greater than 12 weeks.&#xD;
&#xD;
          7. Adequate organ function.&#xD;
&#xD;
          8. Female: child bearing potential, a negative urine or serum pregnancy test result&#xD;
             within 72 h before study treatment. Participants of reproductive potential must be&#xD;
             willing to use adequate contraception for the course of the study through 3 months&#xD;
             after the last dose of SHR-1210.&#xD;
&#xD;
          9. Patient has given written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have or are currently undergoing additional chemotherapy, radiation&#xD;
             therapy, targeted therapy or immunotherapy.&#xD;
&#xD;
          2. Complete obstruction of the esophagus, or patients who have the potential to develop&#xD;
             perforation&#xD;
&#xD;
          3. Other malignancy within 5 years prior to entry into the study, expect for curatively&#xD;
             treated basal cell and squamous cell carcinoma of the skin and/or curatively resected&#xD;
             in-situ cervical and/or breast cancers.&#xD;
&#xD;
          4. Known central nervous system (CNS) metastases.&#xD;
&#xD;
          5. Subjects with any active autoimmune disease or history of autoimmune disease.&#xD;
&#xD;
          6. Uncontrolled clinically significant heart disease, including but not limited to the&#xD;
             following: (1) &gt; NYHA II congestive heart failure; (2) unstable angina, (3) myocardial&#xD;
             infarction within the past 1 year; (4) clinically significant supraventricular&#xD;
             arrhythmia or ventricular arrhythmia requirement for treatment or intervention;&#xD;
&#xD;
          7. Active infection or an unexplained fever &gt; 38.5°C during screening or before the first&#xD;
             scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion&#xD;
             of the investigator);&#xD;
&#xD;
          8. History of Interstitial Pneumonia or active non-infectious pneumonitis.&#xD;
&#xD;
          9. Known Human Immunodeficiency Virus (HIV) infection、active Hepatitis B or Hepatitis C.&#xD;
&#xD;
         10. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent.&#xD;
&#xD;
         11. Known history of hypersensitivity to macromolecular protein preparation or any&#xD;
             components of the SHR-1210 formulation.&#xD;
&#xD;
         12. Concurrent medical condition requiring the use of cortisol (&gt;10mg/day Prednisone or&#xD;
             equivalent dose) or other systematic immunosuppressive medications within 14 days&#xD;
             before the study treament. Except: inhalation or topical corticosteroids. Doses &gt; 10&#xD;
             mg/day prednisone or equivalen for replacement therapy.&#xD;
&#xD;
         13. Has received prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small&#xD;
             molecule therapy, or radiation therapy within 4 weeks prior to study Day 1 or not&#xD;
             recovered from adverse events due to a previously administered agent.&#xD;
&#xD;
         14. Received a live vaccine within 4 weeks of the first dose of study medication.&#xD;
&#xD;
         15. Pregnancy or breast feeding.&#xD;
&#xD;
         16. Decision of unsuitableness by principal investigator or physician-in-charge.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hangzhou Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hangzhou Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Shixiu Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Esophageal Squamous Cell Carcinoma</keyword>
  <keyword>Radiation</keyword>
  <keyword>Anti-PD-1 Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Esophageal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

